ライフサイエンスコーパス: preclinical study

1 ased on human genomics (rather than orthodox preclinical studies).

2 accelerated the progress of immunotherapy in preclinical studies.

3 ubverting Wnt-mediated therapy resistance in preclinical studies.

4 type and site of conjugation (Fab and Fc) in preclinical studies.

5 eling and restore cardiac function in recent preclinical studies.

6 and ultimately, eight models were usable for preclinical studies.

7 ies that will need to be evaluated in future preclinical studies.

8 disease (AD) but has largely been ignored in preclinical studies.

9 monitor retinal photoreceptor cell death in preclinical studies.

10 e, phenocopied human immune responses in two preclinical studies.

11 addiction, and some of these are modeled in preclinical studies.

12 m function in mouse models are essential for preclinical studies.

13 n, based on findings from small clinical and preclinical studies.

14 potent and selective candidate for advanced preclinical studies.

15 ouse A(2B)AR, making it a promising tool for preclinical studies.

16 dysfunction are ongoing, as well as numerous preclinical studies.

17 ing sex-dependent differences at all ages in preclinical studies.

18 rs, chemotherapy and/or radiation therapy in preclinical studies.

19 apy against small-cell lung cancer (SCLC) in preclinical studies.

20 ors have shown potential for gene therapy in preclinical studies.

21 and permanent noise-induced hearing loss in preclinical studies.

22 gineered livers for organ transplantation in preclinical studies.

23 g delivery highlighting their performance in preclinical studies.

24 ces and then was utilized in fundamental and preclinical studies.

25 l biodistribution, tumor homing, and fate in preclinical studies.

26 led phase 2 and 3 trials, and also pertinent preclinical studies.

27 derived cells have been investigated in many preclinical studies.

28 quality is a main cause of discrepancies in preclinical studies.

29 t enough (IC50 approximately 53 nM) to enter preclinical studies.

30 LINGO-1) has shown remyelinating activity in preclinical studies.

31 rstanding molecular mechanisms and advancing preclinical studies.

32 rowth inhibition in RTK-activated cancers in preclinical studies.

33 unotherapy have shown antitumour activity in preclinical studies.

34 s a widely applied technique in clinical and preclinical studies.

35 following active or passive immunization in preclinical studies.

36 tion have limited the translational value of preclinical studies.

37 romising results in both clinical trials and preclinical studies.

38 In a preclinical study, 23 human donor livers underwent 6 hou

39 In preclinical studies, 35 completely inhibited ADO product

40 In preclinical studies, 5-fluoro-2'-deoxycytidine (FdCyd),

41 A total of 22 preclinical studies (816 animals) were included.

42 In a randomized-blinded preclinical study, a single subcutaneous low-dose SMN-AS

43 The majority of preclinical studies aimed at identifying the neurobiolog

44 d laser (SNL) treatment has shown promise in preclinical studies and a pilot study in intermediate AM

45 HS mouse models and provide a foundation for preclinical studies and a rationale for testing whether

46 Preclinical studies and anecdotal reports show that targ

47 iding views on how to bridge the gap between preclinical studies and clinical translation.

48 In addition, preclinical studies and clinical trials demonstrate the

49 Preclinical studies and clinical trials of SGLT2 inhibit

50 Indeed, preclinical studies and early clinical data have establi

51 Recent advances in preclinical studies and early phase clinical trials offe

52 therapeutic approaches that are supported by preclinical studies and early-phase clinical trials sugg

53 has shown promise as a cancer therapeutic in preclinical studies and early-phase clinical trials.

54 Evidence from preclinical studies and human genome-wide analyses, supp

55 anabolic agent that improves bone healing in preclinical studies and in chronic periodontitis, repres

56 wn broad-spectrum anticonvulsant activity in preclinical studies and seizure models.

57 rove clinical symptoms have shown promise in preclinical studies and subsequently were evaluated in c

58 ine is described, and key findings from both preclinical studies and the GLP-2 clinical development p

59 ve treatment of TNBC and may warrant further preclinical study and potentially future investigation i

60 ous than maximum tolerated dose treatment in preclinical studies, and is currently being tested in th

61 ancer survivors are based on expert opinion, preclinical studies, and observational data.

62 However, most hydrogels tested in preclinical studies are not candidates for minimally inv

63 uggable genome wide) association studies for preclinical studies as the major information source for

64 ected from use of human genomics rather than preclinical studies as the primary source of evidence fo

65 Based on prior preclinical studies, both 2'-O-methoxyethyl (MOE) with a

66 These results show that reproducibility in preclinical studies can be obtained and emphasizes the n

67 highlight how comparing males and females in preclinical studies can lead to the development of novel

68 In preclinical studies CD276 ADCs armed with a conventional

69 On the basis of several preclinical studies, cell-based therapy has emerged as a

70 heart failure, atrial fibrillation, and, in preclinical studies, certain cancers.

71 Based on these preclinical studies, clean-surfaced, faceted gold nanocr

72 Guided in part by preclinical studies, clinical trials have focused on hig

73 In preclinical studies, combination therapy with compound 7

74 cular perturbations of hyperammonemia; these preclinical studies complement previous studies on ammon

75 ate some brain tumors in mice and many other preclinical studies confirmed AuNPs as outstanding radio

76 This preclinical study constitutes a key step toward preventi

77 This preclinical study could have a significant impact for br

78 ignal drug availability, not yet examined in preclinical studies, could be relevant to relapse preven

79 Preclinical studies demonstrate that (223)Ra preferentia

80 Previous preclinical studies demonstrate that active and passive

81 Preclinical studies demonstrate that both GLP-1R agonist

82 Preclinical studies demonstrate that sleep disruption di

83 Preclinical studies demonstrated pegvorhyaluronidase alf

84 Preclinical studies demonstrated that ATR inhibition can

85 Preclinical studies demonstrated that complement promote

86 Our preclinical studies demonstrated that PMSCs have the pot

87 Preclinical studies demonstrated that radiation up-regul

88 Conclusion: This preclinical study demonstrated that 5-fluorouracil alone

89 A randomized, blinded preclinical study demonstrated therapeutic effectiveness

90 This preclinical study demonstrates the potential of repurpos

91 Preclinical studies describing their discovery and mecha

92 covery efforts, and discusses the impacts of preclinical study design and translationally relevant ou

93 JCI, Wachsmuth et al. present the results of preclinical studies designed to evaluate the mechanisms

94 Overall, the number of preclinical studies directly comparing plaque inflammati

95 Here, we present definitive preclinical studies enabling a first-in-human trial of D

96 tioxidative and anti-inflammatory functions, preclinical studies encourage heme oxygenase-1 (HO-1)-in

97 However, almost all preclinical studies evaluate new influenza vaccine candi

98 We herein report preclinical studies evaluating systemic messenger RNA (m

99 This preclinical study examines the feasibility of delivering

100 This review highlights preclinical studies examining how maternal consumption o

101 s for Krabbe's disease, prompted the current preclinical study examining the effects of fingolimod in

102 racterized by emotional hypermnesia on which preclinical studies focus so far.

103 +) T-cell tumor infiltrates was evaluated in preclinical studies following single-agent treatment wit

104 itors in HNSCC patients and motivate further preclinical studies for ERBB and PI3K combination therap

105 This procedure is suitable to conduct preclinical studies for exploring the feasibility and ef

106 ogression and target engagement, advances in preclinical studies for the polyglutamine ataxias and th

107 n (HSP90) have been extensively exploited in preclinical studies for the therapeutic interventions of

108 First, a "Pre-IDEAL" stage describing preclinical studies has been added.

109 tors linked with psychiatric illness, but in preclinical studies have been shown to be necessary comp

110 Preclinical studies have consistently demonstrated alter

111 rest in targeting macrophages in cancer, and preclinical studies have demonstrated efficacy across th

112 Preclinical studies have demonstrated epithelial ablatio

113 gh it is not a mainstream treatment, several preclinical studies have demonstrated that EPA exerts an

114 Preclinical studies have demonstrated that galanin affec

115 Preclinical studies have demonstrated that high mechanic

116 Preclinical studies have demonstrated that the mechanism

117 In addition, a large number of preclinical studies have demonstrated that ultrasound al

118 Indeed, preclinical studies have demonstrated the therapeutic be

119 Preclinical studies have established its role in maintai

120 n women compared with men, most clinical and preclinical studies have focused on male subjects.

121 Preclinical studies have found radiotherapy enhances ant

122 be a viable translational research strategy; preclinical studies have found that the neuroactive cyto

123 At the same time, preclinical studies have highlighted nanotechnology appr

124 Preclinical studies have identified crucial pathways reg

125 Preclinical studies have identified other potential ther

126 Although preclinical studies have in part described this systemic

127 Preclinical studies have mostly focused on modeling righ

128 Recent preclinical studies have reenergized this field and prov

129 While preclinical studies have reported improvement of behavio

130 However, several clinical and preclinical studies have reported that the presence and

131 perties of vitamin C and recent high-profile preclinical studies have revived interest in the utiliza

132 Preclinical studies have shown convincingly in rodent mo

133 Preclinical studies have shown engineered HSPCs could al

134 Preclinical studies have shown profound metabolic health

135 Preclinical studies have shown synergistic antitumour ef

136 Recent preclinical studies have shown that enhancing NMDA recep

137 Preclinical studies have shown that ginger constituents

138 Preclinical studies have shown that inhibition of the nu

139 However, preclinical studies have shown that JAK or PI3K pathway

140 Numerous preclinical studies have shown that LAmB administered in

141 Preclinical studies have shown that magnetic resonance (

142 Preclinical studies have shown that moderate aerobic exe

143 Clinical and preclinical studies have shown that there are sex-based

144 Clinical and preclinical studies have suggested strategies to prevent

145 Recent preclinical studies have suggested that combining these

146 Recent preclinical studies have suggested that it also inhibits

147 Preclinical studies have validated this principle of avi

148 In preclinical studies, high tumour FGFR mRNA expression pr

149 Most preclinical studies in animal atherosclerosis models do

150 e an overview of the knowledge obtained with preclinical studies in animal models of DCD heart transp

151 Preclinical studies in animal models of diabetes have id

152 ith, and mouse models of, cystinosis, and in preclinical studies in cystinotic zebrafish.

153 abase was performed to identify all relevant preclinical studies in DCD heart transplantation.

154 Preclinical studies in male mice suggest that activity o

155 While preclinical studies in model organisms have raised some

156 Preclinical studies in the context of abdominal aortic a

157 alternative for an anti-inflammatory drug in preclinical studies in the near future.

158 delayed tolerance" is presented, and ongoing preclinical studies in the nonhuman primate setting-incl

159 r cells in vitro and antitumor activities in preclinical studies in vivo, only a few have shown poten

160 Preclinical study in a mouse model of CRPC suggests ther

161 We also did a parallel preclinical study in rhesus monkeys to test the protecti

162 Preclinical studies, in vivo, and in vitro studies, in c

163 medicine, generating knowledge and tools for preclinical studies, including drug development and test

164 Preclinical studies indicate that (2R,6R)-hydroxynorketa

165 Preclinical studies indicate that (2R,6R)-hydroxynorketa

166 In addition, preclinical studies indicate that ACKR4 and CCL21 are po

167 Preclinical studies indicate that blockade of the alpha5

168 Clinical and preclinical studies indicate that early postnatal exposu

169 In particular, preclinical studies indicate that females may be more se

170 Compelling preclinical studies indicate that low-dose carbon monoxi

171 Preclinical studies indicate that most antidepressants m

172 DKN2A tumor suppressor in PDAC, clinical and preclinical studies indicate that pharmacological CDK4/6

173 Preclinical studies indicate that radiotherapy synergize

174 Preclinical studies indicate that the ketamine metabolit

175 Several preclinical studies indicate that vascular leakage can b

176 In preclinical studies, intracellular islatravir-triphospha

177 Most preclinical studies involving trigeminovascular neurons

178 or improve the success of immunotherapies in preclinical studies is presented, from immunosuppressive

179 , the use of tissue-engineered constructs in preclinical studies is still hindered by complications s

180 liver to inactive metabolites and because in preclinical studies it showed high exposure at the targe

181 ell established by multiple proof-of-concept preclinical studies, its long-term effect, particularly

182 Evidence from preclinical studies led us to hypothesize that activatio

183 Despite the success in preclinical studies, many mGlu(5) negative allosteric mo

184 In preclinical studies, mesenchymal stem cells (MSCs) have

185 nes, however, have shown poor performance in preclinical studies, most likely because the antigens te

186 Based on preclinical studies, neladenoson bialanate, a first-in-c

187 tudy; 2) age range of 13 to 35 years or, for preclinical studies, nonadult subjects; 3) cannabis and

188 The preclinical studies of 7, including efficacy studies in

189 Evidence from clinical and preclinical studies of both periodontal and periapical l

190 atin-remodeling events have shown promise in preclinical studies of CRPC.

191 Here we review in vitro and preclinical studies of dienone compounds including b-AP1

192 There are many preclinical studies of DMCM pathogenesis, but the human

193 tinence.SIGNIFICANCE STATEMENT There are few preclinical studies of fentanyl relapse, and these studi

194 eral blood mononuclear cells (PBMCs) support preclinical studies of human pathogens, allograft reject

195 d reduces alveolar edema and inflammation in preclinical studies of lung injury, but its therapeutic

196 Comprehensive preclinical studies of Myelodysplastic Syndromes (MDS) h

197 vo and provide a proof of concept for future preclinical studies of nonsense suppression agents in RT

198 This review outlines the microbiology and preclinical studies of omadacycline, including its mecha

199 types that may serve as outcome measures for preclinical studies of PTHS treatments.

200 This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics

201 vioral and cognitive deficits in humans, yet preclinical studies of the effect of inhalants on higher

202 linical practice.Significance: This detailed preclinical study of the long-term effects of widely use

203 ivity and are frequently uniquely expressed, preclinical studies on the suitability of glycans as ant

204 tments have largely failed to translate from preclinical studies, others have shown promising initial

205 Using information from preclinical studies performed over the last 20 years, we

206 Although the subject of intense preclinical study, predictive biomarkers for response an

207 rospective studies, case reports or studies, preclinical studies, prevalence data reports, and non-En

208 This preclinical study provided the scientific basis for the

209 served in humans.SIGNIFICANCE STATEMENT This preclinical study provides a neural substrate for ictal

210 Thus, this preclinical study provides proof-of-concept that combini

211 66-2017 (listed in the Cochrane Library) and preclinical studies published in 1945-2017 (listed in Pu

212 paper of 118 clinical trial reports and 135 preclinical studies published in leading journals in 199

213 Annual numbers of kidney-related preclinical studies remained low between 1945 and 2017 c

214 Many clinical and preclinical studies report higher prevalence and severit

215 er, a perplexing gap exists between the many preclinical studies reporting infarct size reduction wit

216 Through review of preclinical studies, retrospective clinical studies, and

217 Further, preclinical studies reveal beneficial effects and liabil

218 These preclinical studies reveal outcomes with direct relevanc

219 Preclinical studies revealed remarkable efficacies of MA

220 Reporting quality analysis of preclinical studies revealed substantial reporting defic

221 Earth-based preclinical studies show space radiation decreases roden

222 Preclinical studies show that arginine deprivation is sy

223 Preclinical studies show that brolucizumab readily penet

224 Findings from clinical and preclinical studies show that the adolescent brain is pa

225 Preclinical studies show that the dopamine D3 receptor (

226 Preclinical studies showed promising antitumour activity

227 Preclinical studies showed significant disease regressio

228 Because preclinical studies showed that ibrutinib could improve

229 Although this view is consistent with preclinical studies showing a negative impact of prefron

230 lum showed the lowest V (T), consistent with preclinical studies showing little to no specific bindin

231 sed on our findings, and coupled with recent preclinical studies showing the importance of multiple n

232 have been modified and tested in a number of preclinical studies, some of which have led to clinical

233 Preclinical studies suggest epigenetic dysregulation, in

234 These preclinical studies suggest PP(i) modulation as a potent

235 NF-kappaB and AR signaling in CRPC, and the preclinical studies suggest that a novel role for PCAT1

236 The results of preclinical studies suggest that anesthetic drugs admini

237 Both clinical and preclinical studies suggest that antiamyloid strategies

238 Preclinical studies suggest that bb2121, a chimeric anti

239 Preclinical studies suggest that extracellular signal-re

240 To date, preclinical studies suggest that it is possible to devel

241 Overall, these preclinical studies suggest that NDV-3A may serve as an

242 Preclinical studies suggest that programmed death 1 (PD-

243 Recent clinical and preclinical studies suggest that selective activators of

244 llowing spinal cord injury, and results from preclinical studies suggest that some of these strategie

245 In contrast, preclinical studies suggest the opposite sex difference.

246 Despite preclinical studies suggesting efficacy for the anti-tox

247 Evidence from preclinical studies suggests that intrauterine growth re

248 In summary, our preclinical study suggests that targeting PTP1B may be a

249 bitors of individual inflammatory mediators, preclinical studies support using resolution pharmacolog

250 to any humanized IgG1 mAb biotherapeutic for preclinical study support.

251 Thus, our preclinical study supports intrathecally targeting sTNFa

252 Preclinical studies targeting cells with an antibody to

253 Initial preclinical studies that elucidated the biology of the p

254 Lastly, we highlight preclinical studies that hold potential for the treatmen

255 To remain comparable with the preclinical studies that led to Gliadel(R) the same size

256 ovide the rationale and explore the relevant preclinical studies that support the use of ex situ live

257 However, there has been limited progress on preclinical studies that validate the therapeutic potent

258 Out of recent findings from clinical and preclinical studies, the concept of the 'cerebellar conn

259 Yet, in preclinical studies, the contribution of the aged microe

260 ow for high-quality, long-term recordings in preclinical studies, the electrodes are foreign objects

261 course in C3(hu/hu) mice may further enable preclinical studies to assess and validate new therapeut

262 f TEADs and NFIs, indicating a rationale for preclinical studies to block the interaction between YAP

263 o are unclear, delaying the translation from preclinical studies to clinical trials.

264 n the translation of mechanisms derived from preclinical studies to complementary findings in clinica

265 1 antagonist) was compared with SB-705498 in preclinical studies to establish whether an improved eff

266 In this study, we built on our preclinical studies to evaluate the safety and efficacy

267 marker in inflammatory conditions has driven preclinical studies to investigate its application for m

268 These efforts should be complemented by preclinical studies to outline the pathophysiological co

269 ls, establishing the potential for multisite preclinical studies to translate into clinical trials.

270 r pharmacogenomics discovery is conducted in preclinical studies, typically using cell lines and mous

271 The present preclinical study used a porcine AF model to evaluate th

272 Preclinical studies using a variety of approaches to red

273 Preclinical studies using an in vivo mouse model also de

274 s work opens the path to greatly accelerated preclinical studies using fumarate as a biomarker.

275 Preclinical studies using genetically engineered mouse m

276 Preclinical studies using Long Access (LgA) cocaine self

277 Preclinical studies using multiple in vitro nAR-negative

278 red in the context of T1D and facilitated by preclinical studies using the nonobese diabetic (NOD) mo

279 Preclinical studies using the PDX mouse model proved tha

280 The preclinical study using an in vivo mouse model with orth

281 better suppress the RCC progression, and our preclinical study using the in vivo mouse model further

282 A preclinical study using the in vivo mouse model further

283 In preclinical studies, venetoclax enhanced bortezomib acti

284 A preclinical study was performed in a test population of

285 The purpose of this preclinical study was to further explore the use of NeoB

286 In these preclinical studies, we describe ADx-001, an Abeta-targe

287 Based on promising preclinical studies, we have performed a first-time-in-h

288 In a series of preclinical studies, we sought to examine the electrophy

289 In this preclinical study, we examined the effects of delayed de

290 In this preclinical study, we explored the effects of 5-fluorour

291 In this preclinical study, we first demonstrate that a mouse mod

292 In this preclinical study, we investigated the immunogenicity an

293 In this preclinical study, we investigated the protective therap

294 hemotherapy to many cancer cells in multiple preclinical studies, while healthy tissue with functiona

295 pathogenesis and has potential to be used in preclinical studies with an objective to identify therap

296 s a lymphoma immunotherapy were evaluated in preclinical studies with human cells and a murine model.

297 level might have an impact on the outcome of preclinical studies with macaque models.

298 Preclinical studies with rodent and primate models have

299 Although preclinical studies with these drugs fueled this optimis

300 uidance and present the results of promising preclinical studies with XPO1 and menin-MLL inhibitors.